We're standing by & we can help. It's free and confidential.*
Get in touch
Telephone: (212) 558-5500
Fax: (212) 344-5461
New York, NY 10003
Most individuals who contact us have never before filed a lawsuit. Their primary concern is with their health or that of a loved one. They don’t know what their legal rights are; they’re not sure if they even have any. We assist them in a number of ways, including informing them of what their legal options are and the best course for moving forward.
David L. Rosenband is an associate attorney in our Drug and Medical Device Litigation group. Part of the Weitz & Luxenberg family since 2001, his mission is to obtain justice on behalf of individuals who innocently placed their trust in a supposedly safe drug or medical device, only to end up suffering a debilitating or life-threatening injury — or, worse, passing along the injury in the form of a birth defect to an offspring.
Mass-tort litigations in which Mr. Rosenband has been involved include Fen-Phen, Rezulin, Baycol, Guidant defibrillators, Medtronic Sprint Fidelis leads, Zyprexa, Seroquel, Vioxx, Bextra, Celebrex, ReNu with MoistureLoc, Zimmer NexGen Knee, Accutane, and Actos.
He was appointed to act as co-plaintiff liaison counsel in the New York Bextra and Celebrex product liability litigation and, in 2012, he was a member of the trial team responsible for securing a $9-million verdict on behalf of a former Accutane user (who subsequently was diagnosed with ulcerative colitis and forced to undergo numerous operations culminating in removal of her colon).
Mr. Rosenband earned a juris doctor degree from George Washington University Law School and undergraduate degree from Tufts University.
W&L's Ellen Relkin, as lead counsel in the NJ Rejuvenate and ABG II hip stem litigation, played a key role in negotiating the more than $1 billion settlement. Most qualifying plaintiffs will receive $300,000 or more.
W&L helped negotiate one of the largest mass tort settlements in recent history. More than 300 W&L clients are part of the settlement. Claimants had recalled DePuy ASR hips implanted and removed prior to August 31, 2013.